InVivo Therapeutics 2011 Archive

InVivo Therapeutics Co-Founder Dr. Robert S. Langer Awarded Annual Innovation Award from The Economist,
CAMBRIDGE, Mass. (December 12, 2011) — InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today congratulates Robert S. Langer, Sc.D., InVivo co-founder and member of the Company’s Scientific Advisory Board, for his selection as the recipient of the 2011 The Economist annual Innovation Award in Bioscience.
Print PDF

InVivo Therapeutics Executes Deal for New, World-Class Global Corporate Headquarters including Research and cGMP Manufacturing Facilities
CAMBRIDGE, Mass. (December 1, 2011) — InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that it has entered into a multi-year lease for a 21,000 square-foot facility at One Kendall Square in Cambridge, MA.
Print PDF

InVivo Therapeutics to Present at 23rd Annual Piper Jaffray Health Care Conference
CAMBRIDGE, Mass. – November 22, 2011 – InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced CEO Frank Reynolds will present InVivo’s most recent breakthroughs and provide a business update to potential investors during the 23rd Annual Piper Jaffray Health Care Conference. The invitation-only event is set for Nov. 29-30 at the New York Palace in New York, NY.
Print PDF

InVivo Therapeutics Reports Third Quarter Financial Results, Provides Business Update
CAMBRIDGE, Mass. (November 15, 2011) – InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today reported financial results for the three and nine months ended September 30, 2011 and provided a business update.
Print PDF

InVivo Therapeutics’ CEO Frank Reynolds to Appear on KTVK-TV’s Good Morning Arizona
CAMBRIDGE, Mass. (November 7, 2011) – InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that CEO Frank Reynolds will appear on KTVK-TV’s Good Morning Arizona on Thursday, November 10th at 8:15am MST.
Print PDF

InVivo Therapeutics to Present at Lazard Capital Markets
CAMBRIDGE, Mass. (November 4, 2011) – InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that CEO Frank Reynolds will present recent updates and meet one-on-one with investors during the Lazard Capital Markets 8th Annual Healthcare Conference November 15-16 at The Pierre Hotel in New York City.
Print PDF

InVivo Therapeutics CEO Frank Reynolds to judge MIT’s $100k Entreprenurship Competition
October 28, 2011: InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced CEO Frank Reynolds has been selected to serve as a judge in the Massachusetts Institute of Technology’s 22nd Annual $100K Entrepreneurship Competition.
Print PDF

InVivo Therapeutics to Present at the 113th FSX Broker Dealer Conference
CAMBRIDGE, Mass. (October 25, 2011) – InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced CEO Frank Reynolds will showcase InVivo’s most recent breakthroughs and provide a business update to potential investors during the 113th FSX (Financial Services Exchange) Conference set for October 26-29 at the Ritz Carlton in Coconut Grove, Fla.
Print PDF

Spinal Cord Injury Medical Leader Dr. Edward Wirth Joins InVivo Therapeutics as Chief Science Officer
October 17, 2011:Ushering in a new era in the treatment of spinal cord injuries (SCI), InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), announced today that world-renowned spinal cord injury (SCI) researcher Edward Wirth, M.D., Ph.D., will join InVivo as its Chief Science Officer (CSO) effective December 5, 2011.
Print PDF

InVivo Therapeutics Announces Positive Preclinical Data in Contusion Spinal Cord Injury Model
September 21, 2011:InVivo Therapeutics Holdings Corp. (OTC/BB:NVIV.ob – News), a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that in a rodent contusion model of SCI the Company’s proprietary biopolymer scaffold showed positive preliminary data that indicate a therapeutic effect. The technology tested was a biomaterial scaffold implant without drugs or cells and is the subject of a proposed 10-patient pilot study in humans in acute spinal cord injury, which the Company hopes to begin next year.
Print PDF

InVivo Therapeutics Promotes Lauren Mitarotondo to Vice President, Operations as InVivo Prepares for Human Studies
August 12, 2011: InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that Lauren Mitarotondo has been promoted to the newly-created position of Vice President, Operations. Reporting to Frank Reynolds, Chief Executive Officer, Ms. Mitarotondo will be responsible for daily operations including regulatory affairs, facilities, human resources, and strategic partnerships.
Print PDF

InVivo Therapeutics to Present at the 13th Annual Rodman & Renshaw Healthcare Conference
September 8 2011:CAMBRIDGE, Mass. (September 87, 2011) – InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that the Company will be presenting at the 13th Annual Rodman & Renshaw Healthcare Conference being held at the Waldorf Astoria in New York City from September 11th – 13th. Frank Reynolds, CEO of InVivo, will deliver the Company’s corporate presentation and provide an update on its business on Tuesday, September 13th, at 4:05 p.m. Eastern time.
Print PDF

InVivo Therapeutics Conference Call
September 8, 2011: CAMBRIDGE, Mass. – InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that the company will hold a conference call on September 8th at 11:00 a.m. Eastern time during which Frank Reynolds, Chief Executive Officer, will provide a business update.
Attend Conference Call

InVivo Therapeutics Reports Second Quarter Financial Results, Provides Business Update
August 11, 2011: InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today reported financial results for the three and six months ended June 30, 2011 and provided a business update.
Print PDF

InVivo Therapeutics Sponsors Working 2 Walk Spinal Cord Injury Symposium
August 9, 2011: InVivo Therapeutics (OTC/BB: NVIV) today announced the Company’s Platinum level sponsorship of the 6th annual Working 2 Walk Science and Advocacy Symposium, which will take place October 16-18, 2011 in Rockville, Maryland.
Print PDF

InVivo Therapeutics Congratulates Robert S. Langer As The Recipient Of The American Chemical Society’s Priestley Medal
July 18, 2011: InVivo Therapeutics congratulates Robert S. Langer, Sc.D., InVivo co-founder and member of the company’s scientific advisory board, for his selection as the recipient of the American Chemical Society’s (ACS) illustrious Priestley Medal for his distinguished services to chemistry. The Priestly Medal is the highest honor bestowed by the ACS, the world’s largest scientific society. Dr. Langer is the first chemical engineer to win the Priestley Medal in 65 years.
Print PDF

InVivo Therapeutics Appoints Dr. Jonathan Slotkin As Medical Director
July 12, 2011: InVivo Therapeutics today announced the appointment of Jonathan R. Slotkin, M.D. as Medical Director. In this newly created position, Dr. Slotkin’s responsibilities will include assisting with regulatory submissions, clinical and medical reporting and clinical trial monitoring. He also will consult with investors and potential collaborators, physicians and licensing partners, while continuing work as a neurosurgeon at Washington Brain & Spine Institute in Washington, D.C.
Print PDF

InVivo Therapeutics Submits IDE Application to FDA for Spinal Cord Injury Clinical Trial
July 7, 2011: InVivo Therapeutics today announced that the Company has submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) for a proprietary biopolymer scaffolding device to protect and support spinal tissue and prevent secondary injury, including inflammation and glial scarring, following traumatic spinal cord injury.
Print PDF

InVivo Therapeutics Sponsors RISE Above Paralysis Gala
March 22, 2011: InVivo Therapeutics, a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries, today announced its champion-level sponsorship of the annual RISE Above Paralysis Gala in support of the Greater Boston Chapter of the National Spinal Cord Injury Association.
Read More

InVivo Therapeutics CEO Frank Reynolds Named to Irish Small Business 50 by the Irish Echo
March 17, 2011: InVivo Therapeutics, a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries, today announced that the Irish Echo, the Country’s largest circulation Irish American weekly newspaper, has named Frank Reynolds, CEO of InVivo Therapeutics, to its inaugural Irish Small Business 50 list.
Read More

InVivo Therapeutics to Sponsor 2008 Beijing Paralympic Gold Medal Sailing Champion Maureen McKinnon-Tucker in Campaign for 2012 Paralympic Games
March 16, 2011: InVivo Therapeutics, a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries, today announced that it will sponsor Paralympic Gold Medalist Maureen McKinnon-Tuckers Paralympic Sailing Campaign in 2011 and 2012 through her organization Sail, Challenge, Inspire. During this time, McKinnon-Tucker and her teammates will be competing for the chance to defend their 2008 gold medal at the 2012 Paralympic Games in London.
Read More

InVivo Therapeutics Announces Data on Novel Hydrogel Technology in Spinal Cord Injury and Neurosurgical Applications Presented at 2011 Annual Meeting of the AANS/CNS Section on Disorders of the Spine and Peripheral Nerves
March 9, 2011: InVivo Therapeutics, a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that a poster highlighting data from a laboratory investigation of the company’s injectable hydrogel technology for local, controlled-release drug delivery, is being presented at the 2011 Annual Meeting of the American Association of Neurological Surgeons (AANS)/Central Nervous System (CNS) Section on Disorders of the Spine and Peripheral Nerves, which is being held March 9-12 in Phoenix, Arizona.
Read More

InVivo Therapeutics Announces Major Patent Expansion To Include Additional Nervous System Conditions
June 8, 2011: InVivo Therapeutics, a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries, today announced it has expanded the Field of Use of its existing patent license to include parts of the peripheral nervous system, the cavernous nerve surrounding the prostate, the brain, the retina and cranial nerves. InVivo has an exclusive, worldwide license to a broad suite of patents, co-owned by the Massachusetts Institute of Technology and Harvards Childrens Hospital the CMCC License.
Print PDF

InVivo Therapeutics Reports First Quarter 2011 Financial Results
May 16, 2011: InVivo Therapeutics, a medical device company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today reported financial results for the first quarter 2011.
Print PDF

InVivo Therapeutics Receives Prestigious 2011 Apple Award for Top Publication in Breakthrough Spinal Cord Injury Research
April 29, 2011: InVivo Therapeutics, a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that Chief Science Officer Dr. Christopher Pritchard, Ph.D., has been selected as the 2011 recipient of the American Spinal Injury Associations (ASIA) prestigious Apple Award. The award recognizes excellence in publishing in spinal cord injury research across the globe.
Print PDF

InVivo Therapeutics Presents Data on Novel Hydrogel Technology in Spinal Cord Injury and Neurosurgical Applications at 2011 AANS 79th Annual Scientific Meeting
April 7, 2011: InVivo Therapeutics, a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that a poster highlighting data from a laboratory investigation of the companys injectable hydrogel technology for local, controlled-release drug delivery, is being presented at the 79th Annual Meeting of the American Association of Neurological Surgeons (AANS), which is being held April 9-13 in Denver, Colorado.
Print PDF

InVivo Therapeutics Holdings Corp. Reports 2010 Financial Results
March 24, 2011: InVivo Therapeutics Holdings Corp, a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries, today reported financial results for the year ended December 31, 2010..
Print PDF

InVivo Therapeutics Appoints Phil Pereira Director of Manufacturing
February 17, 2011: InVivo Therapeutics, a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that it has appointed Phil Pereira Director of Manufacturing. Mr. Pereira will be responsible for overseeing scale-up, qualification and compliance efforts in the manufacture of InVivo’s lead product candidate, a novel, biocompatible polymer scaffolding device, at the company’s recently opened manufacturing and development facility in Medford, Massachusetts. Mr. Pereira will report to Frank Reynolds, Chief Executive Officer of InVivo Therapeutics.
Print PDF

InVivo Therapeutics to Participate in 3rd Annual Lazard Capital Markets Medical Technology Conference
February 15, 2011: InVivo Therapeutics, a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that it will participate in the 3rd Annual Lazard Capital Markets Medical Technology Conference in Snowbird, Utah, to take place from Wednesday, February 23rd to Friday, February 25th, 2011.
Print PDF